Prot #2102-HEM-101: A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation